Provided by Tiger Trade Technology Pte. Ltd.

CSPC PHARMA

9.280
-0.010-0.11%
Volume:103.68M
Turnover:967.78M
Market Cap:106.92B
PE:24.12
High:9.530
Open:9.060
Low:9.060
Close:9.290
52wk High:11.454
52wk Low:4.502
Shares:11.52B
HK Float Shares:11.52B
Volume Ratio:0.69
T/O Rate:0.90%
Dividend:0.30
Dividend Rate:3.18%
EPS(LYR):0.385
ROE:11.33%
ROA:5.44%
PB:2.85
PE(LYR):24.12
PS:3.63

Loading ...

DIARY-Hong Kong corporate earnings week ahead

Reuters
·
Mar 20

Pharmaceutical Firm Rebrands Following CSPC PHARMA Takeover

Deep News
·
Mar 19

CSPC Pharmaceutical Group Stock Slides 1.8% in Hong Kong, Outperforms Competitors

Dow Jones
·
Mar 19

Earning Preview: CSPC PHARMA this quarter’s revenue is expected to increase by 31.04%, and institutional views are bullish

Earnings Agent
·
Mar 18

CSPC Pharmaceutical Group Stock Rises 0.9% in Hong Kong

Dow Jones
·
Mar 17

CSPC PHARMA Subsidiary CSPC Innovation Reports 2025 Net Loss Attributable to Shareholders

Stock News
·
Mar 16

CSPC Pharmaceutical - FY Net Loss Attributable for CSPC Innovation Pharmaceutical RMB241.1 Mln

THOMSON REUTERS
·
Mar 16

CSPC Innovation Pharmaceutical posts RMB 241.13 million net loss in 2025 as revenue rises 8.93% to RMB 2.16 billion

Reuters
·
Mar 16

CSPC Pharma (01093.HK) Receives NMPA Green Light for Clinical Trials of Inhaled PDE4B Inhibitor SYH2059

Bulletin Express
·
Mar 16

CSPC PHARMA's Novel High-Selective PDE4B Inhibitor Receives Clinical Trial Approval in China

Stock News
·
Mar 16

CSPC Pharmaceutical wins China clinical trial approval for SYH2059 inhalation therapy

Reuters
·
Mar 16

CSPC Pharmaceutical - Syh2059 Powder for Inhalation Obtains FDA Clinical Trial Approval in U.S. in March 2026

THOMSON REUTERS
·
Mar 16

CSPC Pharmaceutical Group Stock Climbs 5.1% in Hong Kong, Outperforms Competitors

Dow Jones
·
Mar 16

CSPC PHARMA (01093) Schedules 25 March 2026 Board Meeting for FY2025 Results and Final Dividend Deliberation

Bulletin Express
·
Mar 13

CSPC Pharmaceutical Group to hold board meeting to approve annual results and consider final dividend

Reuters
·
Mar 13

CSPC Pharmaceutical Group Stock Slips 2.2% in Hong Kong, Underperforms Competitors

Dow Jones
·
Mar 11

CSPC Pharmaceutical Group Stock Slips 2.3% in Hong Kong, Underperforms Competitors

Dow Jones
·
Mar 09

BRIEF-CSPC Pharmaceutical Says PDE4B Inhibitor Obtains U.S. Clinical Trial Approval

Reuters
·
Mar 06

CSPC PHARMA's Novel High-Selective PDE4B Inhibitor SYH2059 Inhalation Powder Receives US FDA Clearance for Clinical Trials

Stock News
·
Mar 06

CSPC Pharma (01093) Obtains U.S. FDA Approval for Clinical Trials of Highly Selective PDE4B Inhibitor

Bulletin Express
·
Mar 06